Search

Search Constraints

You searched for: Author/Creator Nice, Rachel

Search Results

1. Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients. (2nd September 2021)

2. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Issue 5 (22nd March 2021)

3. COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study. (November 2022)

4. COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. (April 2022)

5. Implications for sequencing of biologic therapy and choice of second anti‐TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti‐TNF therapy (IMSAT) therapeutic drug monitoring study. Issue 8 (29th August 2022)

6. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Issue 10 (26th April 2021)

7. Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study. (February 2023)

8. Patient-led Remote IntraCapillary pharmacoKinetic Sampling (fingerPRICKS) for Therapeutic Drug Monitoring in patients with Inflammatory Bowel Disease. (21st July 2021)

9. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. (May 2019)

10. Understanding anti‐TNF treatment failure: does serum triiodothyronine‐to‐thyroxine (T3/T4) ratio predict therapeutic outcome to anti‐TNF therapies in biologic‐naïve patients with active luminal Crohn's disease?. Issue 5 (29th June 2022)